Evaluation of current diagnostic methods for COVID-19. 2020

Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent responsible for the coronavirus disease of 2019 (COVID-19), which triggers lung failure, pneumonia, and multi-organ dysfunction. This enveloped, positive sense and single-stranded RNA virus can be transmitted through aerosol droplets, direct and indirect contacts. Thus, SARS-CoV-2 is highly contagious and has reached a pandemic level in a few months. Since COVID-19 has caused numerous human casualties and severe economic loss posing a global threat, the development of readily available, accurate, fast, and cost-effective diagnostic techniques in hospitals and in any places where humans spread the virus is urgently required. COVID-19 can be diagnosed by clinical findings and several laboratory tests. These tests may include virus isolation, nucleic acid-based molecular assays like real-time polymerase chain reactions, antigen or antibody-based immunological assays such as rapid immunochromatographic tests, enzyme-linked immunosorbent assays, immunofluorescence techniques, and indirect fluorescent antibody techniques, electrochemical sensors, etc. However, current methods should be developed by novel approaches for sensitive, specific, and accurate diagnosis of COVID-19 cases to control and prevent this outbreak. Thus, this review will cover an overview and comparison of multiple reports and commercially available kits that include molecular tests, immunoassays, and sensor-based diagnostic methods for diagnosis of COVID-19. The pros and cons of these methods and future perspectives will be thoroughly evaluated and discussed.

UI MeSH Term Description Entries

Related Publications

Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
November 2020, Diagnosis (Berlin, Germany),
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
August 2020, ACS infectious diseases,
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
April 2021, Journal of pharmaceutical analysis,
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
October 2021, Anti-cancer agents in medicinal chemistry,
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
July 2020, Microorganisms,
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
January 2021, Journal of analysis and testing,
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
May 2022, Current pharmaceutical design,
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
February 2021, Expert review of molecular diagnostics,
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
July 2022, Environmental science and pollution research international,
Saadet Alpdagtas, and Elif Ilhan, and Ebru Uysal, and Mustafa Sengor, and Cem Bulent Ustundag, and Oguzhan Gunduz
July 2022, Talanta,
Copied contents to your clipboard!